Meet Ernest Hawk, M.D.
Ernest Hawk, M.D., MPH
Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences
About Dr. Hawk
Ernest Hawk, M.D., MPH, is vice president and division head for Cancer Prevention and Population Sciences at The University of Texas MD Anderson Cancer Center and holds the T. Boone Pickens Distinguished Chair for Early Prevention of Cancer. Additional responsibilities include leadership of the Duncan Family Institute for Cancer Prevention and Risk Assessment, and co-leadership of MD Anderson’s Cancer Prevention and Control Platform which advances community health promotion and cancer control through evidence-based public policy, public and professional education, and community-based service implementation and dissemination.
A native of Detroit, MI, Dr. Hawk earned his bachelor’s and medical degrees at Wayne State University and his master of public health degree at Johns Hopkins University. He completed an internal medicine internship and residency at Emory University, a medical oncology clinical fellowship at the University of California, San Francisco and a cancer prevention fellowship at the National Cancer Institute (NCI).
Prior to his appointment at MD Anderson in December 2007, Dr. Hawk held several positions at the NCI in Bethesda, MD. He most recently served as director of the Office of Centers, Training and Resources, responsible for the NCI’s cancer centers program, a major translational science program (i.e., the SPORE program), the NCI’s extramural training enterprise, and its extramural disparities portfolio. His prior NCI posts included Chief and medical officer in the Gastrointestinal and Other Cancers Research Group, medical officer in the Chemoprevention Branch, and chair of the Translational Research Working Group.
Dr. Hawk has been involved in a wide range of preclinical and clinical chemoprevention research, including developmental studies of nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, and preventive agent combinations in high-risk cohorts. He earned numerous awards for his work, including the NCI Research Award for Distinguished Achievement in Cancer Prevention and the Distinguished Alumnus Award; as well as the ASCO/American Cancer Society Award. Most recently, his interests have broadened to include improvement of minority and underserved populations’ participation in clinical research, and the integration of risk assessment, behavioral science, and preventive strategies developed through sequential clinical trials for application in clinical or public health settings. He has published more than 175 scientific articles and book chapters, edited three books, and serves as the senior deputy editor for Cancer Prevention Research, and on the editorial board of Cancer Medicine.
For more information or to discuss issues related to any of Hawk’s areas of responsibility, you may contact him by calling 713-792-3900. You may also arrange a meeting through his executive assistant Cheri McClellan, by calling 713-745-0176 or via e-mail to cjmcclel@mdanderson.org
Present Title & Affiliation
Primary Appointment
Vice President, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Division Head, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Executive Director, Duncan Family Institute for Cancer Prevention and Risk Assessment, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Boone Pickens Distinguished Chair for Early Prevention of Cancer, Department of Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Cancer Prevention and Control
Translational Research
Molecular Intersections between Cancer and Other Diseases
Education & Training
Degree-Granting Education
| 1994 | Johns Hopkins University School Of Hygiene & Pub Health, Baltimore, MD, USA, MPH, Epidemiology/Biostatistics |
| 1985 | Wayne State University School of Medicine, Detroit, MI, USA, MD, Medicine |
| 1981 | Wayne State University, Detroit, MI, USA, BS, Biological Sciences |
Postgraduate Training
| 1993-1996 | Research Fellowship, Cancer Prevention Fellowship, National Cancer Institute, Bethesda, MD |
| 1991-1993 | Clinical Fellowship, Medical Oncology Clinical Fellowship, University Of California, San Francisco, San Francisco, CA |
| 1985-1988 | Clinical Internship, Internal Medicine Internship/Residency, Emory University Affiliated Hospitals, Atlanta, GA |
Board Certifications
| 2013 | American Board of Internal Medicine - Recertification in Medical Oncology |
| 2003 | American Board of Internal Medicine - Recertification in Medical Oncology |
| 1993 | American Board of Internal Medicine - Diplomate in Medical Oncology |
| 1988 | American Board of Internal Medicine - Diplomate in Internal Medicine |
| 1986 | National Board of Medical Examiners - Diplomate |
Experience & Service
Administrative Appointments/Responsibilities
CCSG, Associate Director, Community Outreach and Engagement, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - Present
Department Chair ad interim, Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2016
CCSG, GI Cancer Program Co-Leader, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present
Co-Director, Cancer Prevention & Control Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - Present
Department Chair ad interim, Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2011
CCSG, Associate Director for Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - Present
Department Chair ad interim, Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2007 - 2009
Other Appointments/Responsibilities
Member, CCSG Site Visit Dana Farber Cancer Institute (Virtual), National Cancer Institute, Bethesda, MD, 2021 - 2021
Member, External Advisory Board, Knight Cancer Institute OHSU, Portland, OR, 2021 - Present
Member, Human Tumor Atlas Network (HTAN), National Cancer Institute, Bethesda, MD, 2021 - Present
Ad Hoc Reviewer, NCI Dissemination and Implementation Conference Committee, Bethesda, MD, 2021 - 2021
Member, MUSC/Hollings Cancer Center, Charleston, SC, 2020 - Present
Chair / External Advisory Board, Mayo Clinic Cancer Center, Rochester, MN, 2020 - 2020
Member, External Advisory Board, VCU Massey Cancer Center, Virginia Survivor Cohort UG3/UH3 Study, Richmond, VA, 2020 - Present
Member, The V Foundation for Cancer Research, Cary, NC, 2020 - Present
At-Large Member, Women's Leadership Network Steering Committee, Houston, TX, 2020 - 2022
Member, FY21 Lung Moon Shot Executive Steering Committee, Houston, TX, 2020 - Present
Member, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, 2020 - Present
Member, CCSG Site Visit Vanderbilt-Ingram Cancer Center, National Cancer Institute, Nashville, TN, 2020 - 2020
Member, Clinical Workgroup, UTH-MDA Population Health Initiative, Houston, TX, 2019 - Present
Chair / Community Outreach and Engagement External Advisory Board, Mayo Clinic Cancer Center, Rochester, MN, 2019 - 2019
Member, Howard-Hopkins Partnership Steering Committee (PSC), Howard University CC and Sidney Kimmel Comp CC @ Johns Hopkins, Baltimore, MD, 2019 - Present
Member, Mission Boost Grant review committee, American Cancer Society, Atlanta, GA, 2019 - 2019
Member, External Advisory Board, Massey Cancer Center at Virginia Commonwealth University, Richmond, VA, 2019 - Present
Member, External Advisory Board, Rutgers/Cancer Institute of New Jersey, New Brunswick, NJ, 2019 - Present
Member, Search Committee for the Director of Cancer Prevention, Office of the Director, National Cancer Institute, Bethesda, MD, 2019 - Present
Member, Physician Scientist Oncology Training Program External Advisory Committee, UT Southwestern Medical Center, Dallas, TX, 2018 - Present
Member, NCI Ideas Workshop, National Cancer Institute, Bethesda, MD, 2018 - 2019
Member, Clinical Trials and Translational Research Advisory Committee (CTAC), National Cancer Institute, Bethesda, MD, 2018 - Present
Chair, Internal Advisory Committee, Puerto Rico Community Center Control Outreach Program, Houston, TX, 2018 - Present
Member, CCSG Site Visit Memorial Sloan Kettering Cancer Center, National Cancer Institute, New York, NY, 2018 - 2018
Member, External Scientific Advisory Committee, Albert Einstein Cancer Center, Bronx, NY, 2018 - Present
Member, CCSG Site Visit City of Hope, National Cancer Institute, Los Angeles, CA, 2017 - 2017
Member, Cancer Prevention Committee, National Cancer Institute, Bethesda, MD, 2017 - Present
Member, Advisory Group, University of New Mexico Project ECHO, Albuquerque, NM, 2017 - 2019
Member, External Advisory Board, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, 2017 - Present
Member, External Advisory Panel (ad hoc), Fred Hutchinson Cancer Research Center, Seattle, WA, 2017 - 2017
Participant, Blue Ribbon Panel Working Group on Precision, Prevention and Early Detection, Washington, DC, 2016 - Present
Member, President's Advisory Council (formerly Shared Governance Committee), Houston, TX, 2015 - Present
Member, Board of Directors, CATCH Global Foundation, Austin, TX, 2015 - 2021
Member, Executive Clinical Operations Team, Houston, TX, 2015 - Present
Ad Hoc Reviewer, NCI Scientific Steering Committee, Bethesda, MD, 2015 - Present
Member, External Advisory Board, Fred & Pamela Buffett Cancer Center at the University of Nebraska Medical Center, Omaha, NE, 2015 - Present
Member, NCI, Int'l Cancer Control Partners Steering Committee, Bethesda, MD, 2015 - 2020
Member, External Advisory Board, UT Southwestern Medical Center, Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, 2011 - Present
Member, CCSG Review Advisory Board (ad hoc), Arizona Cancer Center, Tucson, AZ, 2009 - 2009
Member / External Scientific Advisory Board, Ohio State University Comprehensive Cancer Center - James Cancer Hospital, Columbus, OH, 2008 - 2017
Member / External Advisory Board, Kansas University Cancer Center, Kansas City, KS, 2008 - Present
Member / External Advisory Board, University of Utah - Huntsman Cancer Center, Salt Lake City, UT, 2008 - Present
Member / External Advisory Board, Roswell Park Cancer Institute, Buffalo, NY, 2008 - Present
Member / Scientific Advisory Committee, Harris County-Hospital and University National Children's Study, Houston, TX, 2008 - Present
Member / External Advisory Board, Mayo Clinic Cancer Center, Rochester, MN, 2008 - Present
Institutional Committee Activities
Co-Chair, 2021 Rogers Award Selection Committee, 2021 - 2021
Member, Global Oncology Strategy Workgroup, 2021 - Present
Team Lead, Service Line Teams, 2021 - Present
Member, Research Policy Advisory Council, 2021 - Present
Member, Strategic Position Management Committee, 2020 - Present
Member, Internal Advisory Board, Promoting HPV Vaccination among Young Adults in Texas, 2020 - Present
Member, Internal Advisory Board, Sarcoma SPORE, 2019 - Present
Member, Internal Advisory Board, Mexican-American Cohort Study, 2018 - Present
Member, Network Advisory Committee, 2018 - Present
Member, Shared Resource Executive Committee, 2018 - Present
Executive Committee Member, Komen Training Program to Reduce Breast Cancer Disparities in Black and Hispanic Women, 2018 - 2020
Member, Institutional Biospecimen Utilization Committee (IBUC), 2017 - Present
Member, Women and Minority Faculty Inclusion Advisory Committee, 2016 - Present
Member, Medical Quality Planning Committee, 2014 - 2019
Member, International Advisory Board, 2014 - 2016
Honors & Awards
| 2015 | ASCO/American Cancer Society Award and Lecture |
| 2015 | 2015 Provost's Distinguished Faculty Mentor Nominee, The University of Texas MD Anderson Cancer Center |
| 2014 | Cancer Prevention Fellowship Distinguished Alumni Award, National Cancer Institute, Department of Health & Human Services |
| 2011 | Outstanding Leading Mentor in Cancer Prevention, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center |
| 2007 | The Nancy Terner Behrman Lecture in Honor of Betty Flehinger, PhD, Weill Cornell Medical School, NYC |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Hawk ET, Maresso KC. The ASPREE Trial: An Unanticipated Stimulus for Greater Precision in Prevention?. J Natl Cancer Inst 113(3):221-222, 2021. e-Pub 2020. PMID: 32778864.
- Tami-Maury I, Suchil L, Reynales-Shigematsu LM, Garcia-Gomez L, Chen M, Shete S, Betancur A, Cinciripini PM, Hawk E, Garcia H. Cross-sectional survey for assessing cancer care providers' characteristics and attitudes on smoking cessation in Colombia and Mexico. BMJ Open 11(2):e041447, 2021. e-Pub 2021. PMID: 33526497.
- Torres HA, Lok AS, Suarez-Almazor ME, Warneke CL, Kaseb A, Miller E, Sturgis EM, Foreman JT, Angelidakis G, Ahmed S, Ferrajoli A, Samaniego F, Hawk ET, Hwang JP. Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study. Support Care Cancer 29(1):97-105, 2021. e-Pub 2020. PMID: 32314052.
- Kripke M, Brody JG, Hawk E, Hernandez AB, Hoppin PJ, Jacobs MM, Rudel RA, Rebbeck TR. Rethinking Environmental Carcinogenesis. Cancer Epidemiol Biomarkers Prev 29(10):1870-1875, 2020. PMID: 33004408.
- Davis JS, Kanikarla-Marie P, Gagea M, Yu PL, Fang D, Sebastian M, Yang P, Hawk E, Dashwood R, Lichtenberger LM, Menter D, Kopetz S. Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. BMC Cancer 20(1):871, 2020. e-Pub 2020. PMID: 32912193.
- Liao Y, Basen-Engquist KM, Urbauer DL, Bevers TB, Hawk E, Schembre SM. Using Continuous Glucose Monitoring to Motivate Physical Activity in Overweight and Obese Adults: A Pilot Study. Cancer Epidemiol Biomarkers Prev 29(4):761-768, 2020. e-Pub 2020. PMID: 32066620.
- Abu-Sbeih H, Ali FS, Qiao W, Lum P, Shafi MA, Bresalier RS, Hawk E, Raju GS, Wang Y. Patients with non-colorectal cancers may be at elevated risk of colorectal neoplasia. J Cancer 11(11):3192-3198, 2020. e-Pub 2020. PMID: 32231724.
- Delacruz RGC, Sandoval IT, Chang K, Miller BN, Reyes-Uribe L, Borras E, Lynch PM, Taggart MW, Hawk ET, Vilar E, Jones DA. Functional characterization of CNOT3 variants identified in familial adenomatous polyposis adenomas. Oncotarget 10(39):3939-3951, 2019. e-Pub 2019. PMID: 31231471.
- Cunningham SA, Yu R, Shih T, Giordano S, McNeill LH, Rechis R, Peterson SK, Cinciripini P, Foxhall L, Hawk E, Shete S. Perceived Cancer-related Risk and Beliefs in Texas: Findings from a 2018 Population-Level Survey. Cancer Epidemiol Biomarkers Prev 28(3):486-494, 2019. e-Pub 2019. PMID: 30700446.
- Coletta AM, Marquez G, Thomas P, Thoman W, Bevers T, Brewster AM, Hawk E, Basen-Engquist K, Gilchrist SC. Clinical factors associated with adherence to aerobic and resistance physical activity guidelines among cancer prevention patients and survivors. PLoS One 14(8):e0220814, 2019. e-Pub 2019. PMID: 31369653.
- Lippman SM, Abate-Shen C, Colbert Maresso KL, Colditz GA, Dannenberg AJ, Davidson NE, Disis ML, DuBois RN, Szabo E, Giuliano AR, Hait WN, Lee JJ, Kensler TW, Kramer BS, Limburg P, Maitra A, Martinez ME, Rebbeck TR, Schmitz KH, Vilar E, Hawk ET. AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health. Cancer Prev Res (Phila) 11(12):735-778, 2018. PMID: 30530635.
- Chang K, Willis JA, Reumers J, Taggart MW, San Lucas FA, Thirumurthi S, Kanth P, Delker DA, Hagedorn CH, Lynch PM, Ellis LM, Hawk ET, Scheet PA, Kopetz S, Arts J, Guinney J, Dienstmann R, Vilar E. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Ann Oncol 29(10):2061-2067, 2018. PMID: 30412224.
- Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev 37(2-3):439-454, 2018. PMID: 30112590.
- Frech S, Muha CA, Stevens LM, Trimble EL, Brew R, Perin DP, Luciani S, Mohar A, Piñeros M, Vidaurre T, Morgan DR, Hawk ET, Schmeler KM, Foxhall LE, Rabadan-Diehl C, Duran D, Rendler-Garcia M, Cazap EL, Santini L, Zoss W, Delgado LB, Pearlman PC, Given L, Hohman K, Lopez MS, Kostelecky B. Perspectives on Strengthening Cancer Research and Control in Latin America Through Partnerships and Diplomacy: Experience of the National Cancer Institute's Center for Global Health. J Glob Oncol(4):1-11, 2018. e-Pub 2018. PMID: 30241245.
- Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncol 4(8):1085-1092, 2018. PMID: 29710228.
- Foxhall L, Moreno M, Hawk E. MD Anderson's Population Health Approaches to Cancer Prevention. Tex Med 114(2):34-41, 2018. e-Pub 2018. PMID: 29393960.
- Lopez MS, Baker ES, Milbourne AM, Gowen RM, Rodriguez AM, Lorenzoni C, Mwaba C, Msadabwe SC, Tavares JH, Fontes-Cintra G, Zucca-Matthes G, Callegaro-Filho D, Ramos-Martin D, Thiago de Carvalho I, Coelho R, Marques RM, Chulam T, Pontremoli-Salcedo M, Nozar F, Fiol V, Maza M, Arora S, Hawk ET, Schmeler KM. Project ECHO: A Telementoring Program for Cervical Cancer Prevention and Treatment in Low-Resource Settings. J Glob Oncol 3(5):658-665, 2017. e-Pub 2016. PMID: 29094102.
- Lin SH, Raju GS, Huff C, Ye Y, Gu J, Chen JS, Hildebrandt MAT, Liang H, Menter DG, Morris J, Hawk E, Stroehlein JR, Futreal A, Kopetz S, Mishra L, Wu X. The somatic mutation landscape of premalignant colorectal adenoma. Gut 67(7):1299-1305, 2017. PMID: 28607096.
- Tripp MK, Gershenwald JE, Davies MA, Garcia J, Gritz ER, Hawk ET, Peterson SK. Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors. JAMA Dermatol 153(2):228-229, 2017. e-Pub 2016. PMID: 27829081.
- Davis JS, Lee HY, Kim J, Advani SM, Peng HL, Banfield E, Hawk ET, Chang S, Frazier-Wood AC. Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic. Open Heart 4(1):e000550, 2017. e-Pub 2017. PMID: 28674622.
- Maresso KC, Hawk E. Cancer Prevention Recommendations: Impact of Adherence. Semin Oncol Nurs 32(3):306-13, 2016. e-Pub 2016. PMID: 27539284.
- Mahon SM, Hawk E. Introduction. Semin Oncol Nurs 32(3):185-6, 2016. e-Pub 2016. PMID: 27539274.
- Hawk ET. Ernest Hawk Discusses the NCI-Designated Cancer Centers' Joint Statement on the HPV Vaccine. Oncology (Williston Park) 30(7), 2016. PMID: 27422108.
- DePinho RA, Hawk E. Cancer prevention in developing countries: a vision for preserving health in Mexico. Salud Publica Mex 58(2):93-96, 2016. PMID: 27557366.
- Umar A, Steele VE, Menter DG, Hawk ET. Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Semin Oncol 43(1):65-77, 2016. e-Pub 2015. PMID: 26970125.
- Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Chilukuri S, Charpiot E, Adelmann CH, Ching G, Nguyen TN, Nicholas C, Thomas VD, Migden M, MacFarlane D, Thompson E, Shen J, Takata Y, McNiece K, Polansky MA, Abbas HA, Rajapakshe K, Gower A, Spira A, Covington KR, Xiao W, Gunaratne P, Pickering C, Frederick M, Myers JN, Shen L, Yao H, Su X, Rapini RP, Wheeler DA, Hawk ET, Flores ER, Tsai KY. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun 7:12601, 2016. e-Pub 2016. PMID: 27574101.
- Akiyama J, Alexandre L, Baruah A, Buttar N, Chandra R, Clark AB, Hart AR, Hawk E, Kandioler D, Kappel S, Krishnadath SK, Sharma A, Singh I, Straub D, Triadafilopoulos G, Umar A, Wolf B. Strategy for prevention of cancers of the esophagus. Ann N Y Acad Sci 1325(1):108-26, 2014. PMID: 25266020.
- Volk RJ, Hawk E, Bevers TB. Should CMS cover lung cancer screening for the fully informed patient?. JAMA 312(12):1193-4, 2014. PMID: 25247511.
- Hawk ET, Habermann EB, Ford JG, Wenzel JA, Brahmer JR, Chen MS, Jones LA, Hurd TC, Rogers LM, Nguyen LH, Ahluwalia JS, Fouad M, Vickers SM. Five National Cancer Institute-designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials: A current view and opportunities for improvement. Cancer 120 Suppl S7:1113-1121, 2014. PMID: 24643649.
- Herbst RS, Hobin JA, Gritz ER, Writing Committee for the AACR Subcommittee on Tobacco and Cancer [Hawk E, Hong WK]. AACR celebrates 50 years of tobacco research and policy. Clin Cancer Res 20(7):1709-18, 2014. PMID: 24691637.
- Xu E, Gu J, Hawk ET, Wang KK, Lai M, Huang M, Ajani J, Wu X. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis 34(12):2750-6, 2013. e-Pub 2013. PMID: 23996928.
- Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG, APC Trial Collaborators, Kubo M, Matsuda K, Dunlop M, Houlston RS, Sieber O, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young J, Baird PN, Ratain MJ, Nakamura Y, Weiss ST, Tomlinson I, Bertagnolli MM. Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res 19(23):6430-7, 2013. e-Pub 2013. PMID: 24084763.
- Hassan MM, Kaseb A, Etzel CJ, El-Serag H, Spitz MR, Chang P, Hale KS, Liu M, Rashid A, Shama M, Abbruzzese JL, Loyer EM, Kaur H, Hassabo HM, Vauthey JN, Wray CJ, Hassan BS, Patt YZ, Hawk E, Soliman KM, Li D. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction. Mol Carcinog 52 Suppl 1:139-47, 2013. e-Pub 2013. PMID: 23776098.
- Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382(9894):769-79, 2013. e-Pub 2013. PMID: 23726390.
- Raju GS, Vadyala V, Slack R, Krishna SG, Ross WA, Lynch PM, Bresalier RS, Hawk E, Stroehlein JR. Adenoma detection in patients undergoing a comprehensive colonoscopy screening. Cancer Med 2(3):391-402, 2013. e-Pub 2013. PMID: 23930215.
- Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E. MicroRNA Expression Signatures during Malignant Progression from Barrett's Esophagus to Esophageal Adenocarcinoma. Cancer Prev Res (Phila) 6(3):196-205, 2013. PMID: 23466817.
- Kumar NB, Dhurandhar M, Aggarwal B, Anant S, Daniel K, Deng G, Djeu J, Dou J, Hawk E, Jayaram B, Jia L, Joshi R, Kararala M, Karunagaran D, Kucuk O, Kumar L, Malafa M, Samathanam GJ, Sarkar F, Siddiqi M, Singh RP, Srivastava A, White JD. Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survival. Cancer Med 2(1):108-15, 2013. PMID: 24279005.
- Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal PA, Golub TR, Hait WN, Lozano G, Maris JM, Nelson WG, Sawyers CL, Schreiber SL, Spitz MR, Steeg PS. AACR Cancer Progress Report 2012. Clin Cancer Res 18(21 Suppl):S1-100, 2012. e-Pub 2012. PMID: 22977188.
- Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Etzel C, Huang M, Hsu CY, Ye Y, Mishra L, Hawk E, Wu X. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst 104(20):1599-611, 2012. PMID: 23073549.
- Dai J, Gu J, Huang M, Eng C, Kopetz ES, Ellis LM, Hawk E, Wu X. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis 33(7):1327-31, 2012. e-Pub 2012. PMID: 22505654.
- Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, Huang M, Calin GA, Wang D, Dubois RN, Hawk ET, Wu X. Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients. Clin Cancer Res 18(14):3982-91, 2012. e-Pub 2012. PMID: 22661538.
- Cialdella-Kam L, Sabado P, Bispeck MK, Silverman S, Bernstein L, Krawiec V, Hawk E, O'Donnell JF. Implementing Cancer Prevention into Clinical Practice. J Cancer Educ 27(Suppl 2):S136-43, 2012. e-Pub 2012. PMID: 22367592.
- Lin M, Eng C, Hawk E, Huang M, Greisinger AJ, Gu J, Ellis LM, Wu X, Lin J. Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. Carcinogenesis 33(4):841-7, 2012. e-Pub 2012. PMID: 22318908.
- Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Bertagnolli MM, Hawk ET, Eagle C, Coindreau J, Zauber A, Lanas A, Levin B. The APC and PreSAP Trials: A Post Hoc Noninferiority Analysis Using a Comprehensive New Measure for Gastrointestinal Tract Injury in 2 Randomized, Double-Blind Studies Comparing Celecoxib and Placebo. Clin Ther 34(3):569-79, 2012. e-Pub 2012. PMID: 22386831.
- Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM. The Influence of UGT1A6 Variants and Aspirin Use in a Randomized Trial of Celecoxib for Prevention of Colorectal Adenoma. Cancer Prev Res (Phila) 5(1):61-72, 2012. e-Pub 2011. PMID: 22030088.
- Lin J, Forman MR, Wang J, Grossman HB, Chen M, Dinney CP, Hawk ET, Wu X. Intake of red meat and heterocyclic amines, metabolic pathway genes, and bladder cancer risk. Int J Cancer 131(8), 2012. e-Pub 2012. PMID: 22261697.
- Ross W, Lynch P, Raju G, Rodriguez A, Burke T, Hafemeister L, Hawk E, Wu X, Dubois RN, Mishra L. Biomarkers, bundled payments, and colorectal cancer care. Genes Cancer 3(1):16-22, 2012. PMID: 22893787.
- Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC, PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104(2):125-32, 2012. e-Pub 2012. PMID: 22228146.
- Fischer SM, Hawk ET, Lubet RA. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila) 4(11):1728-35, 2011. e-Pub 2011. PMID: 21778329.
- Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM. C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment. Cancer Prev Res (Phila) 4(8):1172-80, 2011. PMID: 21816845.
- Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD, PLCO Project Team. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305(22):2295-303, 2011. PMID: 21642681.
- Lin M, Hawk E, Huang M, Lin J, Gu J, Ellis LM, Wu X, Eng C. Identification of polymorphisms in ultraconserved elements (UCEs) associated with clinical outcomes in patients (pts) with stage II/III colorectal cancer (CRC). J Clin Oncol 29(15_suppl):3529, 2011. PMID: 28020328.
- Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Wang KK, Wu X. Chromosomal Aberrations Predict Malignant Progression of Esophageal Adenocarcinoma: a Genome-wide High-Density SNP Array Analysis. Cancer Prev Res (Phila) 3(9):1176-86, 2010. e-Pub 2010. PMID: 20651033.
- Brewster AM, Patterson SL, Forman MR, Hughes-Halbert C, Limburg PJ, Ondrey FG, Paskett ED, Wetter DW, Hawk ET. Conference Report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prev Res (Phila Pa) 3(8):1044-8, 2010. e-Pub 2010. PMID: 20663980.
- Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Half E, Burke CA. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol 105(6):1437-43, 2010. e-Pub 2010. PMID: 20234350.
- Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG. Statin Use and Colorectal Adenoma Risk: Results from the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 3(5):588-96, 2010. e-Pub 2010. PMID: 20403998.
- Hawk E, Patterson S. Modelling a dream: the molecular prevention of pancreatic cancer. Gut 59(5):566-8, 2010. PMID: 20427387.
- Lippman SM, Hawk ET. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res 69(13):5269-84, 2009. e-Pub 2009. PMID: 19491253.
- Chan AT, Zauber AG, Meier H, Breazna A, Hunter DJ, Rosenstein RB, Eagle CJ, Hawk ET, Bertagnolli MM. Cytochrome P450 2C9 Variants Influence Response to Celecoxib for Prevention of Colorectal Adenoma. Gastroenterology 136(7):2127-2136.e1, 2009. e-Pub 2009. PMID: 19233181.
- Mutch MG, Schoen RE, Fleshman JW, Rall CJ, Dry S, Seligson D, Charabaty A, Chia D, Umar A, Viner J, Hawk E, Pinsky PF. A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol 7(5):568-74, 2009. PMID: 19418605.
- Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 2(4):310-21, 2009. e-Pub 2009. PMID: 19336730.
- Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD, PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310-9, 2009. e-Pub 2009. PMID: 19297565.
- Mutch MG, Mph RE, Fleshman JW, Rall CJ, Dry S, Seligson D, Charabaty A, Chia D, Dvm AU, Viner J, Hawk E, Pinsky PF. A Multi-Center Study of Prevalence and Risk Factors for Aberrant Crypt Foci. Clin Gastroenterol Hepatol 7(5), 2009. e-Pub 2009. PMID: 19418605.
- Hawk E, Guillem JG. Improving the Vision of Colonoscopy: Does the Fine Print Really Matter?. Cancer Prev Res (Phila Pa) 1(7):495-498, 2008. PMID: 19138997.
- Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, Lippman SM. Cancer epidemiology, biomarkers & prevention and cancer prevention research: two journals, a common goal. Cancer Prev Res (Phila Pa) 1(6):393-5, 2008. PMID: 19138984.
- Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, Lippman SM. Cancer epidemiology, biomarkers & prevention, and cancer prevention research: two journals, a common goal. Cancer Epidemiol Biomarkers Prev 17(11):2903-5, 2008. PMID: 18990728.
- Hawk ET, Matrisian LM, Nelson WG, Dorfman GS, Stevens L, Kwok J, Viner J, Hautala J, Grad O, Translational Research Working Group. The Translational Research Working Group developmental pathways: introduction and overview. Clin Cancer Res 14(18):5664-71, 2008. e-Pub 2008. PMID: 18612047.
- Srivastava S, Gray JW, Reid BJ, Grad O, Greenwood A, Hawk ET, Translational Research Working Group. Translational Research Working Group developmental pathway for biospecimen-based assessment modalities. Clin Cancer Res 14(18):5672-7, 2008. PMID: 18794074.
- Hawk ET, Greenwood A, Gritz ER, McTiernan A, Sellers T, Hursting SD, Leischow S, Grad O, Translational Research Working Group. The Translational Research Working Group developmental pathway for lifestyle alterations. Clin Cancer Res 14(18):5707-13, 2008. PMID: 18794079.
- Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM, Saltzman JR, Gostout C, Eagle CJ, Hawk ET, Bertagnolli MM. Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 1(1):21-31, 2008. e-Pub 2008. PMID: 19138933.
- Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW. Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial. Cancer Prev Res (Phila Pa) 1(1):32-38, 2008. PMID: 18841250.
- Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E, Cross Trial Safety Assessment Group. Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials The Cross Trial Safety Analysis. Circulation 117(16):2104-13, 2008. e-Pub 2008. PMID: 18378608.
- Hawk ET, Viner JL. Statins in esophageal cancer cell lines: promising lead?. Am J Gastroenterol 103(4):838-41, 2008. e-Pub 2008. PMID: 18371147.
- Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, Forastiere AA, Chemoprevention for Barrett's Esophagus Trial Research Group. Secondary chemoprevention of Barrett's Esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 99(7):545-557, 2007. PMID: 17405999.
- Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A, Workshop Program Committee. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark 3(1):1-33, 2007. PMID: 17655039.
- Hawk E, Viner JL. What is the future of oncology? National Cancer Institute initiatives to improve. research, development, and implementation in cancer prevention and treatment. Semin Oncol 33(11):S6-S9, 2006. PMID: 17178278.
- Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J, APC and PreSAP Trial Investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114(10):1028-1035, 2006. PMID: 16943394.
- Hawk ET, Viner JL. Do statins prevent cancer?. Nat Clin Pract Oncol 3(9):478-9, 2006. PMID: 16955084.
- Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET, APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873-84, 2006. PMID: 16943400.
- Glebov OK, Rodriguez LM, Lynch P, Patterson S, Lynch H, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, Denobile J, Soballe P, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 15(7):1382-1391, 2006. PMID: 16835340.
- Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Taylor PR, Limburg PJ, Dawsey SM, Hawk ET, Qiao YL, Kirsch IR. Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res 66(13):6851-60, 2006. PMID: 16818663.
- Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK, AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res 12(12):3661-97, 2006. PMID: 16778094.
- Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Taylor PR, Limburg PJ, Dawsey SM, Hawk ET, Qiao YL, Kirsch IR. Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev 15(5):1046-7, 2006. PMID: 16702392.
- Jankowski JA, Hawk ET. A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol 3(2):101-11, 2006. PMID: 16456576.
- Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 5(12):930-942, 2005. PMID: 16341084.
- Limburg PJ, Wei W, Ahnen DJ, Qiao Y, Hawk ET, Wang G, Giffen CA, Wang G, Roth MJ, Lu N, Korn EL, Ma Y, Caldwell KL, Dong Z, Taylor PR, Dawsey SM. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology 129(3):863-73, 2005. PMID: 16143126.
- Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071-1080, 2005. e-Pub 2005. PMID: 15713944.
- Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol 23(2):378-91, 2005. PMID: 15637400.
- Hawk ET, Umar A, Lubet RA, Kopelovich L, Viner JL. Can animal models help us select specific compounds for cancer prevention trials?. Recent Results Cancer Res 166:71-87, 2005. PMID: 15648184.
- Hawk ET, Umar A, Richmond E, Viner JL. Prevention and therapy of colorectal cancer. Med Clin North Am 89(1):85-110, viii, 2005. PMID: 15527810.
- Lippman SM, Levin B, Brenner DE, Gordon GB, Aldige CR, Kramer BS, Garber JE, Hawk E, Ganz PA, Somerfield MR, Writing Committee of the ASCO Cancer Prevention Committee. Cancer prevention and the American Society of Clinical Oncology. J Clin Oncol 22(19):3848-3851, 2004. e-Pub 2004. PMID: 15353541.
- Lam S, leRiche JC, McWilliams A, Macaulay C, Dyachkova Y, Szabo E, Mayo J, Schellenberg R, Coldman A, Hawk E, Gazdar A. A randomized phase IIb trial of Pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 10(19):6502-6511, 2004. PMID: 15475437.
- Jacoby RF, Cole CE, Hawk ET, Lubet RA. Ursodeoxycholate/sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology 127(3):838-844, 2004. PMID: 15362039.
- Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 24(5B):3177-3184, 2004. PMID: 15510608.
- Lao CD, Backoff P, Shotland LI, McCarty D, Eaton T, Ondrey FG, Viner JL, Spechler SJ, Hawk ET, Brenner DE. Irreversible ototoxicity associated with difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 13(7):1250-2, 2004. PMID: 15247138.
- Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC, Familial Adenomatous Polyposis Study Group. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 13(6):920-7, 2004. PMID: 15184247.
- Hawk ET, Umar A, Viner JL. Colorectal cancer chemoprevention--an overview of the science. Gastroenterology 126(5):1423-47, 2004. PMID: 15131803.
- Xiao Z, Luke BT, Izmirlian G, Umar A, Lynch PM, Phillips RK, Patterson S, Conrads TP, Veenstra TD, Greenwald P, Hawk ET, Ali IU. Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res 64(8):2904-9, 2004. PMID: 15087410.
- Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch Syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261-268, 2004. PMID: 14970275.
- Umar A, Risinger JI, Hawk ET, Barrett JC. Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer 4(2):153-8, 2004. PMID: 14964310.
- Viner JL, Hawk E. Commentary on Chan, et al. N Am Menopause Soc J 11(3), 2004.
- Anderson WF, Umar A, Hawk ET. Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opin Pharmacother 4(12):2193-204, 2003. PMID: 14640918.
- Hawk ET, Viner JL. Aspirin: still learning about the wonder drug. Gut 52(11):1535-6, 2003. PMID: 14570718.
- Sabichi AL, Demierre MF, Hawk ET, Lerman CE, Lippman SM. Frontiers in cancer prevention research. Cancer Res 63(18):5649-55, 2003. PMID: 14522879.
- Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, DeNobile J, Soballe P, Simon R, Wright G, Lynch P, Patterson S, Lynch H, Gallinger S, Buchbinder A, Gordon G, Hawk E, Kirsch IR. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev 12(8):755-762, 2003. PMID: 12917207.
- Umar A, Viner JL, Anderson WF, Hawk ET. Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol 26(4):S48-57, 2003. PMID: 12902856.
- Steele VE, Hawk ET, Viner JL, Lubet RA. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res 523-524:137-44, 2003. PMID: 12628511.
- Hawk E, Viner JL, Umar A, Anderson WF, Sigman C, Guyton KZ. Cancer and the cyclooxygenase enzyme - Implications for prevention and treatment. Amer J Cancer 2:27-55, 2003.
- Heath EI, Canto MI, Wu TT, Piantadosi S, Hawk E, Unalp A, Gordon G, Forastiere AA, CBET Research Group. Chemoprevention for Barrett's esophagus trial. Design and outcome measures. Dis Esophagus 16(3):177-86, 2003. PMID: 14641306.
- Hawk ET, Viner J, Richmond E, Umar A. Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. Cancer Chemother Biol Response Modif 21:759-89, 2003. PMID: 15338773.
- Viner JL, Umar A, Hawk ET. Chemoprevention of colorectal cancer: problems, progress, and prospects. Gastroenterol Clin North Am 31(4):971-99, 2002. PMID: 12489273.
- Hawk ET, Limburg PJ, Viner JL. Epidemiology and prevention of colorectal cancer. Surg Clin North Am 82(5):905-41, 2002. PMID: 12507200.
- Anderson WF, Guyton KZ, Hiatt RA, Vernon SW, Levin B, Hawk E. Colorectal cancer screening for persons at average risk. J Natl Cancer Inst 94(15):1126-1133, 2002. PMID: 12165637.
- Lam S, MacAulay C, Le Riche JC, Dyachkova Y, Coldman A, Guillaud M, Hawk E, Christen MO, Gazdar AF. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 94(13):1001-9, 2002. PMID: 12096085.
- Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G, FAP Study Group. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50(6):857-860, 2002. PMID: 12010890.
- Umar A, Viner JL, Richmond E, Anderson WF, Hawk ET. Chemoprevention of colorectal carcinogenesis. Int J Clin Oncol 7(1):2-26, 2002. PMID: 11942045.
- Umar A, Viner JL, Hawk ET. The future of colon cancer prevention. Ann N Y Acad Sci 952:88-108, 2001. PMID: 11795446.
- Dimitrov NV, Leece CM, Tompkins ER, Seymour E, Bennink M, Gardiner J, Crowell J, Hawk E, Nashawaty M, Bennett JL. Oltipraz concentrations in plasma, buccal mucosa cells, and lipids - pharmacological studies. Cancer Epidemiol Biomarkers Prev 10(3):201-208, 2001. PMID: 11303588.
- Anderson WF, Hawk E, Berg CD. Secondary chemoprevention of upper aerodigestive tract tumors. Semin Oncol 28(1):106-20, 2001. PMID: 11254870.
- Hawk ET, Viner JL, Anderson BF. Development of COX inhibitors as cancer chemopreventives. ASCO Educational Book Spring:28-37, 2001.
- Kelloff GJ, Sigman CC, Hawk ET, Johnson KM, Crowell JA, Guyton KZ. Surrogate end-point biomarkers in chemopreventive drug development. IARC Sci Publ 154:13-26, 2001. PMID: 11220652.
- Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC, Kelloff GJ. Potential use of lipoxygenase inhibitors for cancer chemoprevention. Expert Opin Investig Drugs 9(9):2121-38, 2000. PMID: 11060797.
- Hawk ET, Lippman SM. Primary cancer prevention trials. Hematol Oncol Clin North Am 14(4):809-30, 2000. PMID: 10949775.
- Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342(26):1946-52, 2000. PMID: 10874062.
- Hawk E, Breslow RA, Graubard BI. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 9(5):523-7, 2000. PMID: 10815699.
- Hawk E, Viner JL, Lawrence JA. Biomarkers as surrogates for cancer development. Curr Oncol Rep 2(3):242-50, 2000. PMID: 11122849.
- Heath EI, Limburg PJ, Hawk ET, Forastiere AA. Adenocarcinoma of the esophagus: risk factors and prevention. Oncology (Williston Park) 14(4):507-14; discussion 518-20, 522-3, 2000. PMID: 10826312.
- Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET, Lubet RA. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 60(7):1864-70, 2000. PMID: 10766173.
- Kelloff GJ, Sigman CC, Johnson KM, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev 9(2):127-37, 2000. PMID: 10698472.
- Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, Kopelovich L, Hawk ET, Lieberman R, Lawrence JA, Ali I, Viner JL, Sigman CC. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 130(2S Suppl):467S-471S, 2000. PMID: 10721931.
- van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, Kresty L, Kemmenoe BH, Elson P, Rybicki L, Church J, Provencher K, McLain D, Hawk E, Fryer B, Kelloff G, Ganapathi R, Budd GT. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 6(1):78-89, 2000. PMID: 10656435.
- Hawk E, Lubet R, Limburg P. Chemoprevention in hereditary colorectal cancer syndromes. Cancer 86(11 Suppl):2551-63, 1999. PMID: 10630181.
- McCaskill-Stevens W, Hawk ET, Flynn PJ, Lippman SM. National Cancer Institute--supported cancer chemoprevention research: coming of age. J Clin Oncol 17(11 Suppl):53-62, 1999. PMID: 10630263.
- Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, Sigman CC, Kelloff GJ. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 8(5):467-83, 1999. PMID: 10350444.
- Lam S, leRiche JC, Zheng Y, Coldman A, MacAulay C, Hawk E, Kelloff G, Gazdar AF. Sex-related differences in bronchial epithelial changes associated with tobacco smoking. J Natl Cancer Inst 91(8):691-6, 1999. PMID: 10218506.
- Li H, Schut HA, Conran P, Kramer PM, Lubet RA, Steele VE, Hawk EE, Kelloff GJ, Pereira MA. Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 20(3):425-30, 1999. PMID: 10190557.
- Shao J, Sheng H, Aramandla R, Pereira MA, Lubet RA, Hawk E, Grogan L, Kirsch IR, Washington MK, Beauchamp RD, DuBois RN. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 20(2):185-91, 1999. PMID: 10069452.
- Hawk ET, Limburg PJ. Agent development in colorectal cancer chemoprevention: current status and future trends. ASCO Educational Book Spring:193-199, 1999.
- Stoner GD, Budd GT, Ganapathi R, DeYoung B, Kresty LA, Nitert M, Fryer B, Church JM, Provencher K, Pamukcu R, Piazza G, Hawk E, Kelloff G, Elson P, van Stolk RU. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol 470:45-53, 1999. PMID: 10709673.
- Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Boone CW, Malone WA, Hawk ET, Lieberman R, Lawrence JA, Kopelovich L, Ali I, Viner JL, Sigman CC. Progress in cancer chemoprevention. Ann N Y Acad Sci 889:1-13, 1999. PMID: 10668477.
- Hawk E, Limburg P, Lubet R. Chemoprevention in hereditary colorectal cancer. Cancer 86:1731-43, 1999.
- Lieberman R, Crowell JA, Hawk ET, Boone CW, Sigman CC, Kelloff GJ. Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring. Clin Chem 44(2):420 7, 1998. PMID: 9474054.
- Kelloff GJ, Lubet RA, Lieberman R, Eisenhauer K, Steele VE, Crowell JA, Hawk ET, Boone CW, Sigman CC. Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 7(1):65-78, 1998. PMID: 9456245.
- Kelloff GJ, Hawk ET, Karp JE, Crowell JA, Boone CW, Steele VE, Lubet RA, Sigman CC. Progress in clinical chemoprevention. Semin Oncol 24(2):241-252, 1997. PMID: 9129692.
- Hawk E, Doeltz MK, Kelloff GK. Indomethacin - toxicology and safety. Contribution to IARC Handbooks of Cancer Prevention - Non-steroidal Anti-inflammatory Drugs (International Agency for Research on Cancer, Lyon) 1:151-197, 1997.
- Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk ET, Steele VE, Lubet RA, Sigman CC. Perspectives and progress in development of breast cancer chemopreventive drugs. Prog Clin Biol Res 396:159-183, 1997. PMID: 9108597.
- Kelloff GJ, Hawk ET, Crowell JA, Boone CW, Steele VE, Lubet RA, Sigman CC. Perspectives on chemoprevention agent selection and short-term clinical prevention trials. Eur J Cancer Prev 5(suppl 2):79-85, 1996. PMID: 9061299.
- Kelloff GJ, Hawk ET, Crowell JA, Boone CW, Nayfield SG, Perloff M, Steele VE, Lubet RA. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology (Williston Park) 10(10):1471-84; discussion 1484-8, 1996. PMID: 8905841.
- Rao KV, Detrisac CJ, Steele VE, Hawk ET, Kelloff GJ, McCormick DL. Differential activity of aspirin, ketoprofen, and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 17(7):1435-8, 1996. PMID: 8706245.
- Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet RA, Greenwald P, Hawk ET, Fay JR, Sigman CC. Mechanistic considerations in the evaluation of chemopreventive data. IARC Sci Publ 139(139):203-219, 1996. PMID: 8923032.
- Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Malone WF, Steele VE, Lubet RA, Sigman CC. Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem Suppl 25S:1-14, 1996. PMID: 9027592.
- Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet RA, Doody LA, Malone WF, Hawk ET, Sigman CC. New agents for cancer chemoprevention. J Cell Biochem Suppl 26S:1-28, 1996. PMID: 9154166.
- Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, Covey JM, Doody LA, Omenn GS, Greenwald P, Hong WK, Parkinson DR, Bagheri D, Baxter GT, Blunden M, Doeltz MK, Eisenhauer KM, Johnson K, Knapp GG, Longfellow DG, Malone WF, Nayfield SG, Seifried HE, Swall LM, Sigman CC. Strategy and planning for chemopreventive drug development: Clinical Development Plans II. J Cell Biochem Suppl 26S:54-71, 1996. PMID: 9154168.
- Kelloff GJ, Hawk ET, Crowell JA, Boone CW, et al. Chemoprevention of cancer - strategies for identification and clinical evaluation of promising agents. Oncology 10:1471-91, 1996.
- Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Steele VE, Lubet RA, Sigman CC. Strategies for Phase II cancer chemoprevention trials: Cervix, endometrium, and ovary. J Cell Biochem Suppl Supp 23:1-9, 1995. PMID: 8747372.
- Kelloff G, Boone C, Crowell J, Nayfield S, Hawk E, et al.. Development of breast cancer chemopreventive drugs. The Breast Journal 1:271-83, 1995.
- Lin M, Eng C, Hawk ET, Huang M, Lin J, Gu J, Ellis LM, Wu X. Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. Cancer 118(24). e-Pub 2012. PMID: 22673945.
- Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood A, Hawk ET. Convergence of Nanotechnology and Cancer Prevention: Are We There Yet?. Cancer Prev Res (Phila). e-Pub 2014. PMID: 25060262.
- Satcher RL, Bogler O, Hyle L, Lee A, Simmons A, Williams R, Hawk E, Matin S, Brewster AM. Telemedicine and telesurgery in cancer care: Inaugural conference at MD Anderson Cancer Center. J Surg Oncol. e-Pub 2014. PMID: 24889208.
- Hildebrandt MA, Reyes ME, Lin M, He Y, Nguyen SV, Hawk ET, Wu X. Germline genetic variants in the Wnt/beta-catenin pathway as predictors of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. e-Pub 2016. PMID: 26809274.
- Tsai KY, Hawk ET. When "Effective" Prevention Agents Fail to Elicit Anticipated Effects: Challenges in Trial Design. Cancer Prev Res (Phila). e-Pub 2015. PMID: 26714773.
- Wu X, Hildebrandt MA, Ye Y, Chow WH, Gu J, Cunningham S, Zhao H, Hawk ET, Wagar E, Rodriguez A, Hamilton SR. Cohort Profile: The MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC). Int J Epidemiol. e-Pub 2015. PMID: 26686840.
- Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: Current status and future directions. CA Cancer J Clin. e-Pub 2015. PMID: 26284997.
- Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, Hawk E, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology. e-Pub 2015. PMID: 25836985.
- Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Wang X, Liu J, Patterson S, Sinicrope FA, Rodriguez-Bigas MA, Half E, Bulow S, Latchford A, Clark S, Ross WA, Malone B, Hasson H, Richmond E, Hawk E. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut. e-Pub 2015. PMID: 25792707.
- Mackert M, Case K, Lazard A, Oh J, Wagner JH, Hawk E, Cofer J, Hurst A, Elerian N, Lakey D. Building a Health Communication Brand for University of Texas System Tobacco Control. J Am Coll Health:0. e-Pub 2018. PMID: 29952736.
- Hernandez M, Hernández-Valero MA, García-Prieto C, Patterson DG, Hajek RA, Recinos I, Lopez DS, Li Y, Jones LA, Hawk E. A Pilot Study Evaluating Organochlorine and Organophosphate Pesticide Exposure in Children and Adolescents of Mexican Descent Residing in Hidalgo County, Texas. J Immigr Minor Health. e-Pub 2018. PMID: 30066057.
- Golemis EA, Scheet P, Beck TN, Scolnick E, Hunter DJ, Hawk E, Hopkins N. Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev. e-Pub 2018. PMID: 29945886.
- Sivakumar S, San Lucas FA, McDowell TL, Lang W, Xu L, Fujimoto J, Zhang J, Futreal PA, Fukuoka J, Yatabe Y, Dubinett SM, Spira AE, Fowler J, Hawk ET, Wistuba II, Scheet P, Kadara H. Genomic landscape of atypical adenomatous hyperplasia reveals divergent modes to lung adenocarcinoma. Cancer Res. e-Pub 2017. PMID: 28951454.
- Ornelas A, Zacharias-Millward N, Menter DG, Davis JS, Lichtenberger L, Hawke D, Hawk E, Vilar E, Bhattacharya P, Millward S. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. e-Pub 2017. PMID: 28762014.
- Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev. e-Pub 2017. PMID: 28730545.
- Gausachs M, Borras E, Chang K, González S, Azuara D, Delgado Amador A, Lopez-Doriga A, San Lucas FA, Sanjuan X, Paules MJ, Taggart M, Davies G, Ehli EA, Fowler J, Moreno V, Pineda M, You YN, Lynch PM, Lazaro C, Navin NE, Scheet P, Hawk ET, Capella G, Vilar E. Mutational Heterogeneity in APC and KRAS Arises at the Crypt level and Leads to Polyclonality in Early Colorectal Tumorigenesis. Clin Cancer Res. e-Pub 2017. PMID: 28645942.
- Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. e-Pub 2017. PMID: 28579181.
- Hurd TC, Kaplan CD, Cook ED, Chilton JA, Lytton JS, Hawk ET, Jones LA. Building trust and diversity in patient-centered oncology clinical trials: An integrated model. Clin Trials:1740774516688860. e-Pub 2017. PMID: 28166647.
- Borras E, San Lucas FA, Chang K, Zhou R, Masand G, Fowler J, Mork ME, You YN, Taggart MW, McAllister F, Jones DA, Davies GE, Edelmann W, Ehli EA, Lynch PM, Hawk ET, Capella G, Scheet P, Vilar E. Genomic Landscape of Colorectal Mucosa and Adenomas. Cancer Prev Res (Phila). e-Pub 2016. PMID: 27221540.
- Rechis R, Oestman KB, Caballero E, Brewster A, Walsh MT, Basen-Engquist K, Gershenwald JE, Tektiridis JH, Moreno M, Williams PA, Treiman K, Garza PD, Hawk E. Be Well Communities™: mobilizing communities to promote wellness and stop cancer before it starts. Cancer Causes Control. e-Pub 2021. PMID: 34037915.
- Guimarães DP, Mantuan LA, de Oliveira MA, Junior RLH, Mafra da Costa A, Rossi S, Fava G, Taveira LN, Giardina KM, Talarico T, Costa M, Scapulatempo-Neto C, M Matsushita M, Véo CAR, Fregnani JHT, Reis RM, Hawk ET, Mauad EC. The performance of colorectal cancer screening in Brazil: the first two years of the implementation program in Barretos Cancer Hospital. Cancer Prev Res (Phila). e-Pub 2020. PMID: 32998941.
- Liao, Y., Basen-Engquist, K. M., Urbauer, D. L., Bevers, T. B., Hawk, E., & Schembre, S. M.. Design of a novel physical activity intervention in overweight and obese adults using continuous glucose monitoring: A pilot study. Cancer Epidemiol Biomarkers Prev 29(4):761-768.
- Hawk ET, Colbert Maresso K. E-Cigarettes: Unstandardized, Under-regulated, Understudied - and Unknown Health and Cancer Risks. Cancer Res. e-Pub 2019. PMID: 31658978.
- Chido-Amajuoyi OG, Mantey D, Cunningham S, Yu R, Kelder S, Hawk E, Cinciripini P, Shete S. Characteristics of us adults attempting tobacco use cessation using e-cigarettes. Addict Behav 100:106123. e-Pub 2019. PMID: 31605837.
- Fokom Domgue J, Baker E, Manjuh F, Lopez M, Welty T, Schmeler KM, Cameroon Cervical Cancer Prevention ECHO collaborative group. Connecting frontline providers in Africa with distant experts to improve patients' outcomes through Project ECHO: a successful experience in Cameroon. Int J Gynecol Cancer. e-Pub 2019. PMID: 31118215.
- Huey RW, Hawk E, Offodile AC. Mind the Gap: Precision Oncology and Its Potential to Widen Disparities. J Oncol Pract:JOP1900102. e-Pub 2019. PMID: 31112478.
- Sivakumar S, San Lucas FA, Jakubek YA, McDowell TL, Lang W, Kallsen N, Peyton S, Davies GE, Fukuoka J, Yatabe Y, Zhang J, Futreal PA, Fowler J, Fujimoto J, Ehli EA, Hawk ET, Wistuba II, Kadara H, Scheet P. Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine. e-Pub 2019. PMID: 30905849.
- Zacharias NM, Ornelas A, Lee J, Hu J, Davis J, Uddin MN, Pudakalakatti S, Menter D, Karam JA, Wood CG, Hawk E, Kopetz S, Vilar E, Bhattacharya P, Millward S. Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. Angew Chem Int Ed Engl. e-Pub 2019. PMID: 30680862.
Invited Articles
- Dahlstrom KR, Sturgis EM, DePinho RA, Hawk E, Baum GP, Tamez E, Bello RS, Stevens LD, Ramondetta LM. Knowledge About the Human Papillomavirus Vaccine Among Employees at a Tertiary Cancer Center: Room for Improvement. J Appl Res Child 10(2), 2020.
- Maresso KC, Hawk ET. A New Year, A Healthier You: 5 actions to reduce your cancer risk. Magazine of the National Association of Petroleum Engineers (NAPE):42-44, 2020.
- Patterson SL, Maresso KC, Hawk E. Cancer Chemoprevention, Successes and Failures. Clin Chem 59(1):94-101, 2013. e-Pub 2012. PMID: 23150056.
- Lin J, Wang J, Greisinger AJ, Grossman HB, Forman MR, Dinney CP, Hawk ET, Wu X. Energy Balance, the PI3K-AKT-mTOR Pathway Genes, and the Risk of Bladder Cancer. Cancer Prev Res 3(4):505-17, 2010. e-Pub 2010. PMID: 20354165.
- Hawk E, Patterson S. Aspirin: Anti-Colorectal Adenocarcinoma Activity in the Adjuvant Arena?. Future Oncol 6(2):197-200, 2010. PMID: 20146578.
- Hawk E, Patterson S. Statins: Assessing their Effects on Cancer Risk. NYP Cancer Prevention Newsletter(14), 2010.
- Colbert Maresso K, Vilar E, Hawk ET. Urinary PGE-M in Colorectal Cancer: Predicting More than Risk?. Cancer Prev Res (Phila). e-Pub 2014. PMID: 25070664.
Other Articles
- National Academies of Sciences, Engineering, and Medicine Reflections on Sharing Clinical Trial Data: Challenges and a Way Forward: Proceedings of a Workshop.
Editorials
- Hawk, ET, Maresso KC. Aspirin Use and Cancer Prevention: Long-Term Data Needed on Benefits and Risks. The ASCO Post, 2019.
- Hawk E, Maresso KC, Brown P. NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question. J Natl Cancer Inst 110(9):927-928, 2018. PMID: 29554350.
- Brenner DE, Hawk E. Trials and Tribulations of Interrogating Biomarkers to Define Efficacy of Cancer Risk Reductive Interventions. Cancer Prev Res (Phila) 6(2), 2013. PMID: 23333813.
- Hawk E, Viner JL. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress. Cancer Epidemiol Biomarkers Prev 16(2):185-7, 2007. PMID: 17301246.
- Hawk E, Viner JL. Statins and cancer - beyond the "one drug-one disease" model. N Engl J Med 352(21):2238-2239, 2005. PMID: 15917390.
- Hawk E, Viner JL. The critical role of risk-benefit assessments in cancer prevention. Cancer Epidemiol Biomarkers Prev 14(2):297-8, 2005. PMID: 15734949.
- Kelloff GJ, O'Shaughnessy JA, Gordon GB, Hawk ET, Sigman CC. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev 12(7):593-6, 2003. PMID: 12869396.
- Hawk ET, Viner JL, Dannenberg A, DuBois RN. COX-2 in cancer--a player that's defining the rules. J Natl Cancer Inst 94(8):545-6, 2002. PMID: 11959883.
- Hawk ET, Viner JL. Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research. Ann Intern Med 134(2):158-60, 2001. PMID: 11177320.
- Vilar E, Maresso KC, Hawk ET. Aspirin for Cancer Prevention: One Step Closer. JAMA Oncol. PMID: 26939883.
Abstracts
- Hassan M, Li D, Kaseb A, Abbruzzese JL, Hassabo H, Aly M, Sahin I, Morris J, Hawk E, Spitz M. Early Obesity and Risk of Hepatocellular Carcinoma in USA: Assessment of Environmental, Dietary, and Biological Risk Factors Impacting Liver Cancer Incidence in Texas. Society of Toxicology (SOT) Annual Meeting, 2013.
- Hawk E. Clinical Agent Development for Colorectal Cancer Prevention. J Cell Commun Signal, 2013.
- Lynch P, Burke C, Phillips R, Wang X, Liu J, Morris J, Patterson S, Sinicrope F, Rodriguez-Bigas M, Half E, Bulow S, Latchford A, Hasson H, Richmond E, Hawk E. An International, Randomized Trial of Celecoxib versus Celecoxib plus Difluoromethylornithine in Patients with Familial Adenomatous Polyposis. DDW, 2012.
- Foxhall L, Patterson S, Silvas E, Galendez M, Furlan E and Hawk E. Comprehensive Cancer Control Plan Implementation at an NCI Comprehensive Cancer Center. Poster presentation, CPRIT – Innovations in Cancer Prevention and Research Conference, 2011.
- Burke C, Lynch P, Hawk E, Phillips R. Is hearing loss an extracolonic manifestation of FAP?. Proc Am C Gastro, 2006.
- Lynch P, Burke C, Hawk E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Benfield R, Half E, Miller D, Ayes GD. Colonoscopy in a phase I safety trial of celecoxib in children with FAP. Familial Cancer 4:57, 2005.
- Burke CA, Lynch PM, Phillips R, Hawk E, Church J, Hasson H, Miller D, Burke S. Considerations for maximizing randomization in chemoprevention trials in FAP. Familial Cancer 4:76-77, 2005.
- Burke C, Hawk E, Eagle C, Wolog M, Church J, Hasson H, Patterson S, Benfield R, Half E, Miller D, Ayers GD, Lynch PM. Design and primary safety outcome in a phase I trial of celecoxib in children with FAP. Familial Cancer 4:77-8, 2005.
- Lynch P, Burke C, Hawk E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Half E, Ayers D. Efficacy and safety in a phase I safety trial of celecoxib in children with FAP. AGA, 2005.
- Peterson SK, Askins MA, Watts BG, Burke CA, Hasson H, Church J, Schover LR, Hawk E, Lynch PM. Family resiliency and functioning among families with APC-positive children. Familial Cancer 4:49-50, 2005.
- Peterson SK, Lynch PM, Burke C, Church J, Hasson H, Hawk E. Psychosocial evaluation of children and parents involved in a phase I study of celecoxib in children with FAP. CGA, 2004.
- Half E, Su L-K, Lunagomez S, Steinbach G, Patterson S, Phillips RK, Latchford A, Hawk E, Lynch PM. Response to celecoxib in familial adenomatous polyposis (FAP) does not depend on genotype or adenoma burden. DDW, 2004.
- Lynch PM, Steinbach G, Hittelman W, Terry N, Frazier M, Abbruzzese J, Gordon G, Hawk E, Kirsch I, Lynch H. A Phase II Chemoprevention Trial in HNPCC utilizing a selective Cyclooxygenase 2 inhibitor; protocol description and progress to date. J Gastroenterol Hepatol 14(8):A59, 1999.
- Steinbach G, Lynch PM, Phillips R, Wallace M, Hawk E, Gordan G, Sherman J, Wakabayashi N, Saunders B, Shen Y, Godio L, Patterson S, Abbruzzese J, Jester S, King K, Zimmerman S, Levin B. Effect of celecoxib on colorectal polyps in patients with familial adenomatous polyposis (FAP). Am J Gastroenterol, 1999.
Book Chapters
- Basen-Engquist K, Brown P, Coletta AM, Colbert Maresso K, and Hawk E. Lifestyle and Cancer Prevention. In: Abeloff's Clinical Oncology. Sixth. Elsevier: Philadelphia, 337-374, 2018.
- Bevers TB, El-Serag H, Hanash S, Thrift AP, Tsai K, Colbert Maresso K, and Hawk E. Screening and Early Detection. In: Abeloff's Clinical Oncology. Sixth. Elsevier: Philadelphia, 375-398, 2018.
- Menter DG, Davis JS, Tucker SC, Hawk E, Crissman JD, Sood AK, Kopetz S, Honn KV. Platelets: "First Responders" in Cancer Progression and Metastasis. In: Platelets in Thrombotic and Non-Thrombotic Disorders Pathophysiology, Pharmacology and Therapeutics: an Update. Springer International Publishing AG: Switzerland, 1111-1132, 2017.
- Bevers TB, Brown PH, Colbert Maresso K, and Hawk ET. Cancer Prevention, Screening and Early Detection. In: Abeloff's Clinical Oncology. Fifth. Elsevier: Philadelphia, 322-359, 2014.
- Colbert Maresso K and Hawk E. Designing the Chemoprevention Trials of Tomorrow: Applying Lessons Learned from Past Definitive Trials. In: Cancer Prevention: Dietary Factors and Pharmacology. Humana Press: New York, 265-284, 2014.
- Hawk ET, Patterson SL, Mishra L, Patel KK. Colorectal Cancer Prevention and Aging. In: Cancer and Aging Handbook Research and Practice. John Wiley & Sons, Inc: New Jersey, 85-96, 2012.
- Wu X, Patterson S, Hawk E. Chemoprevention - History and General Principles. In: Best Pract Res Clin Gastroenterol. 4-5, 445-59, 2011.
- Viner JL, Hawk E, Lippman S. Cancer chemoprevention. In: Cancer Epidemiology and Prevention. Third. Oxford Univ. Press: Oxford, 1318-1340, 2006.
- Hawk ET, Viner JL, Limburg PJ. Chapter 52 - Epidemiology and prevention of colorectal cancer. In: Gastrointestinal Oncology. Oxford University Press: New York, 593-634, 2003.
- Hawk E, Sigman CC, Kelloff G. Prevention of gastrointestinal cancers. In: Gastrointestinal Oncology. Saunders: Edinburgh, 205-214, 2003.
- Watson AJM, Hawk E, DuBois RN. Chemoprevention of colorectal cancer. In: Gastrointestinal Oncology. Saunders: Edinburgh, 421-428, 2003.
- Hawk ET, Viner JL, Umar A. Non-steroidal anti-inflammatory and cyclooxygenase-2 selective inhibitors in clinical cancer prevention trials. In: Prog Exp Tumor Res. Karger Press: Basel, 210-242, 2003.
- Hawk E. COX-2 in cancer. In: Ravnetrykk - Targeted Cancer Therapies, An Odyssey. Tromso University Press: Tromso, 92-95, 2003.
- Viner J, Lawrence J, Richmond E, Hawk E. Cancer chemoprevention. In: Cancer Handbook. MacMillan Publishers: Hampshire, Chapter 90, 2002.
- Anderson WF, Umar A, Viner JL, Hawk ET. Potential role of NSAIDs and COX-2 blockade in cancer therapy. In: Cyclooxygenase 2 (COX-2) Blockade in Cancer Prevention and Therapy. Humana Press, Inc: Totowa, NJ, 313-340, 2002.
- Anderson WF, Umar A, Viner JL, Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. In: Curr Pharm Des. 12, 1035-62, 2002.
- Schatzkin A, Goldstein A, Hawk E. Chemo- and dietary prevention of familial cancer: from theory to practice. In: Familial cancer and prevention: molecular epidemiology: a new strategy. Wiley-Liss: New York, 295-301, 1999.
Books (edited and written)
- Jankowski J, Hawk E. Handbook of Gastrointestinal Cancer. Wiley-Blackwell of John Wiley & Sons, Ltd: West Sussex, UK, 2013.
- Teicher B.. Cancer Chemoprevention - Strategies for Cancer Chemoprevention. In: Cancer Drug Discovery and Development Series. Ed(s) GJ Kelloff, E Hawk, CC Sigman. The Humana Press: Totowa, NJ, 560, 2005.
- Teicher B.. Cancer Chemoprevention - Promising Cancer Chemopreventive Agents. In: Cancer Drug Discovery and Development Series. Ed(s) GJ Kelloff, E Hawk, CC Sigman. The Humana Press: Totowa, NJ, 600, 2004.
Letters to the Editor
- Hawk E, Prindiville S, Kelloff G. NSAID trials, sporadic adenomas, and conservative inferences. Gastroenterology 110(2): 654-5, 1996.
Grant & Contract Support
| Title: | Cancer Center Support Grant |
| Funding Source: | NIH/NCI |
| Role: | Member, CCSG Senior Leadership/Associate Director Population Sciences; Director Community Outreach and Engagement; Co-Leader GI Program |
| Title: | Cancer Prevention Agent Development Program |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Improving Cervical Cancer Screening and Prevention in the Lower Rio Grande Valley Through Public Outreach, Patient Navigation, and Telementoring |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Program Director |
| Title: | Genome-Wide Association Study in Hepatocellular Carcinoma (GWAS Study) |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator (Year 5) |
| Title: | Integrative Analysis of Sequencing Data for Adenoma Development |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Administrative Supplements for NCI-designated Cancer Centers to Support Population Health Assessment in Cancer Center Catchment Areas |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | The Role of Methyl Donors in Cancer Risk |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | INCan Collaborative Development of a Curriculum in Cancer Prevention and Control for the Institute Nacional de Cancerologia in Mexico |
| Funding Source: | CRDF Global |
| Role: | Principal Investigator |
| Title: | Aspirin-PC for Chemoprevention of Colorectal Cancer |
| Funding Source: | PLX Pharma |
| Role: | Co-Investigator |
| Title: | Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations: Expansion of cervical cancer prevention services to medically underserved populations through patient outreach, navigation, and provider training/telementoring |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Program Director |
| Title: | Project 3: Non-Invasive Assessment of Liver Fibrosis Stage and Progression in Obesity and Diabetes: A Hispanic Population Study |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | Advances in our understanding of the mechanisms of obesity and radiation in carcinogenesis, and personalized cancer etiology |
| Funding Source: | John Templeton Foundation |
| Role: | Co-Investigator |
| Title: | Be Well Communities(TM): A Model for Cancer Prevention & Control in Underserved Communities |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |